Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Pharma and BRIC supplement

- PMLiVE

Almirall celebrates new offices in China to advance innovation in dermatology

The company’s R&D and commercial expertise represent valuable capabilities for future Chinese partners

- PMLiVE

AstraZeneca announces $2.5bn investment in China to boost R&D capabilities

The funds will go towards a new global research and development centre in Beijing’s BioPark

- PMLiVE

Infographic: Rare Diseases in China

How rare are rare diseases in China? Download this infographic to find out more and how we can offer guidance for pharma companies to consider.

Inizio

- PMLiVE

Webcast: China Update 2023: How will recent developments impact your brand’s success?

Register for this live webinar in which emerging market experts provide an update regarding the implications of changing demographics and the healthcare landscape.

Inizio

- PMLiVE

Sanofi and Innovent Biologics to develop oncology drugs for patients in China

Sanofi will make an initial equity investment of €300m in Innovent

- PMLiVE

Novo Nordisk growth takes a hit with China deal

Danish diabetes specialist Novo Nordisk cuts its growth forecast for 2022 following a value-based procurement deal with the Chinese government for its insulin products

- PMLiVE

Sinopharm’s COVID-19 vaccine scores approval in China

Vaccine found to be 79% effective in top-line results

- PMLiVE

Russia says its Sputnik V COVID-19 vaccine is 91.4% effective

Preliminary data demonstrates efficacy of 95% after 42 days

Webcast

China: How pharma can maximize success in this rapidly changing emerging market

Inizio

- PMLiVE

Russia submits COVID-19 vaccine to WHO for emergency use listing

Russia became first country to grant approval to a COVID-19 vaccine in August

China flag thumb

Experimental Chinese COVID-19 vaccine is safe, according to researchers

Safety data was published on pre-print server medRxiv

- PMLiVE

Russia’s COVID-19 vaccine demonstrates early potential in Lancet report

However, there is too little data to definitively confirm efficacy

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links